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Abstract 
Objective: Syndecan-4 (sdc4) is a cell-anchored proteoglycan that consists of a 
transmembrane core protein and glucosaminoglycan (GAG) side chains. Binding of soluble 
factors to the GAG-chains of sdc4 may result in the dimerization of sdc4 and the initiation of 
downstream signaling cascades. However, the question of how sdc4 dimerization and 
signaling affects the response of cells to inflammatory stimuli is unknown.  
Methods: Sdc4 immunostaining was performed on rheumatoid arthritis (RA) tissue sections. 
Interleukin (IL)-1 induced ERK phosphorylation and MMP3 production was investigated. Il-1 
binding to sdc4 was investigated using immunoprecipitation. IL-1 receptor (IL-1R) staining on 
wildtype, sdc4 and il1R1 knockout fibroblasts was performed in FACS analyses. A blocking 
sdc-4 antibody was used to investigate sdc-4 dimerization, il1-R1 expression and the 
histological paw destruction in the hTNFtg mouse. 
Results: We show that in fibroblasts the loss of sdc4 or the antibody-mediated inhibition of 
sdc4 dimerization reduces the cell surface expression of the IL-1R and regulates the 
sensitivity of fibroblasts to IL-1. We demonstrate that IL-1 directly binds to sdc4 and in an IL-
1R independent manner leads to its dimerization. IL-1 induced dimerization of Sdc4 
regulates caveolin vesicle-mediated trafficking of the IL-1R1, which in turn determines the 
responsiveness to IL-1. Administration of antibodies against the dimerization domain of sdc4, 
thus, strongly reduces the expression IL-1R1 on arthritic fibroblasts both in vitro and an 
animal model of human rheumatoid arthritis.  
Conclusion: Collectively, our data suggest that antibodies that specifically inhibit sdc4 
dimerization may support anti-IL-1 strategies in diseases such as inflammatory arthritis. 
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Introduction: 
Human rheumatoid arthritis (RA) is a systemic autoimmune disease that primarily affects the 
joints and that is characterized by chronic inflammation, progressive cartilage destruction and 
bone erosions [1]. Resident fibroblast-like synoviocytes (FLS) in the joints have been 
implicated prominently in the progression of disease, in which early cartilage damage 
appears to be of pivotal importance [2]. These FLS exhibit an autonomously aggressive 
phenotype that is maintained in the absence of continuous inflammatory stimulation [3]. The 
transformation of FLS in rheumatoid arthritis is associated with altered secretion of soluble 
factors such as cytokines and chemokines as well as an enhanced response to inflammatory 
mediators such as IL-1. Although clinical studies targeting IL-1 have shown only limited 
efficacy in established disease [4], a number of studies using both pharmacological inhibition 
of IL-1 and IL-1-deficient mice have identified IL-1 as an important trigger of early arthritic 
cartilage damage with FLS being both an important source of and target cell for IL-1 [5]. We 
have shown previously that the loss of syndecan-4 (sdc4) protects mice from cartilage 
damage in animal models of osteoarthritis [6] and RA [7]. In this context, we also showed 
that chondrocytes lacking sdc4 exhibited a reduced responsiveness to IL-1 with reduced IL-1 
mediated ERK phosphorylation [6]. In these studies, antibodies raised against the 
dimerization domain of sdc4 exhibited a blocking effect on IL-1 induced ERK signalling but 
the mechanism by which the loss or inhibition of sdc4 interfered with IL1 signaling remains 
unclear [6]. Interestingly, recent evidence suggests that trafficking of the IL1-receptor (IL-
1R1) involves the formation of caveolin vesicles [8] and that sdc4 may regulate the caveolin-
mediated endocytosis of signaling molecules such as Rac1 [9] as well as of cell surface 
receptors such as integrins [10].  
Based on these data we studied the mechanisms by which sdc4 regulates IL-1 signaling and 
explored the possibility of specifically interfering with sdc4 regulated IL-1 signaling through 
the delivery of specific antibodies. We report that IL-1 binds to sdc4 and leads to its 
dimerization which regulates caveolin vesicle-mediated trafficking of IL-1R1. Administration 
of antibodies against the dimerization domain of sdc4, thus, strongly desensitizes arthritic 
fibroblasts against IL-1, providing a novel tool for therapeutic intervention in IL-1 mediated 
diseases. 
 
Results 
Scd4 reduces IL-1ß signalling by direct binding to the heparan sulphate (HS) side chains and 
induction of sdc4 dimerization 
We first investigated the expression of sdc4 in human RA as well as in the human TNFalpha 
transgenic (hTNFtg) mouse, an established animal model of the disease. As shown in Fig. 
1a, scd4 was highly expressed in RA synovium, with very prominent staining in the most 
4 
 
superficial lining layer that mediates the attachment to and degradation of articular cartilage. 
In contrast, only very few scd4 expressing cells were found in synovial tissues from OA 
patients. As determined by quantitative real-time PCR, the upregulation was also evident at 
the mRNA level, where RASF expressed 3.5-fold higher levels of scd4 than OASF. These 
data suggested that the inflammatory environment in the RA synovium leads to a strong and 
sustained upregulation of scd4 in synovial fibroblasts. To further investigate if chronic 
exposure to TNFalpha results in a sustained upregulation of scd4 in synovial fibroblasts, 
hTNFtg mice were analyzed for the expression of scd4. As seen in immunohistochemistry, 
there was a strong expression of scd4 in the synovial membranes of hTNFtg (Fig. 1b) mice, 
whereas only negligible staining for scd4 was found in synovial tissues of wild type animals. 
In vitro, synovial fibroblasts isolated from hTNFtg mice showed more than 21.6-fold higher 
expression of scd4 than wild type controls (Fig. 1b). 
TNFα and IL-1β both have been shown to be of importance for FLS activation in RA. In 
Western blot analyses, we found that loss of Sdc4 in FLS did not affect of ERK activation in 
response to TNF alpha (Fig. 1c). However, Sdc4 deficiency in FLS significantly reduced IL-
1ß dependent phosphorylation of ERK1/2 (Figure 1d). Next, we asked the question if 
reduction in IL-1β induced ERK- signalling in Sdc4-/- FLS would translate into reduced 
expression of disease-relevant matrix metalloproteinases (MMPs). When investigating the 
expression of MMP-3 in cell culture supernatants of TNFα and IL-1ß stimulated FLS from 
wild type and Sdc4-/- mice we found that, again, TNF alpha induced expression of MMP-3 
was not different between wild type and Sdc4-/- FLS (Fig. 1e). However, stimulation of Sdc4-
/- FLS with IL-1ß led to significantly lower levels of MMP-3 compared to those from IL-1 
stimulated wild type controls (wt: 151.41 ± 5.02, Scd4-/-: 77.13 ± 8.36, p=0.001)(Fig. 1f). 
These findings made us wonder whether there is a direct interaction between Sdc4 and the 
cytokines IL-1ß and TNFα. To this end, we transfected HEK cells either with FLAG tagged 
full length sdc4 (flag-sdc4wt) or with a FLAG-tagged mutant of sdc4 lacking the attachment 
sites for GAG side chains (flag-sdc4S3A). We found that unlike TNF alpha, which showed no 
interaction with either flag-sdc4wt or with flag-sdc4S3A, IL-1β bound to flag-sdc4wt but not to 
flag-sdc4S3A (Fig. 1g), indicating that the GAG chains of Sdc4 mediated the binding of IL-1. 
Next, we were interested to see if IL-1β could induce dimerization of Sdc4, which has been 
described to be a key step in sdc4 mediated signal transduction [11]. Interestingly, IL-1β 
induced dimerization of sdc4 was also observed in FLS lacking the IL-1R1 (Fig. 1h), 
suggesting that the dimerization of sdc4 is a direct effect of IL-1 binding and not a secondary 
effect due to IL-1 receptor signalling. As shown in Fig. 1i, stimulation of NIH3T3 fibroblasts 
with IL-1 resulted in dimerization of sdc4, which was stabilized using the chemical cross-
linker BS3. Obviously no dimers were detectable in the Sdc4-/- fibroblasts and in unstimulated 
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NIH/3T3 fibroblasts even after crosslinking. Wildtype FLS transfected with wt-sdc4-plasmid 
served as positive control. 
 
Sdc4 regulates IL1R1 trafficking upon Il-1 stimulation 
These data made us wonder about the mechanisms by which sdc4 regulates the sensitivity 
of FLS to IL-1. Using flow cytometry analyses, we found that the loss of sdc4 was associated 
with a significant reduction of IL1R1 surface expression on FLS (wt: 9.77 ± 0.77, sdc4: 1.94 ± 
0.19, IL-1R1: 0.52 ± 0.04, p=0.0006) (Fig. 2a). Importantly, mRNA levels of IL-1R1 were 
unaltered in sdc4-/- cells compared to wt (Fig. 2b), indicating that sdc4 does not regulate 
IL1R1 expression but rather affects translational processes and/or trafficking of the IL1R1. 
The lack of sdc4 had no influence on the expression of the TNF receptor 1 (TNFR1) either on 
the cell surface as determined by FACS analysis (wt: 7.38 ± 0.5, sdc4: 7.47 ± 0.43, IL-1R1: 
8.47 ± 0.20, p= 0.9056) (Fig. 2c), or at the mRNA level (Fig. 1d). To investigate the time 
kinetics of IL1R1 surface presentation we performed FACS analyses of the IL1R1 at 10 
minutes as well as, 3 and 5 hours following IL-1 stimulation. We observed a significant 
reduction in Il1R1 at the cell surface in wt fibroblasts after 10 minutes (0.92 ± 0.02, p= 
0.0286), which was recovered after 3 hours (1.04 ± 0.07). This effect was not observed in 
sdc4-/- fibroblasts (sdc4 t10: 0.89 ± 0.04, sdc4 t3h: 0.85 ± 0.04) (Fig. 2e). Because the 
trafficking of the IL1R1 involves the formation of caveolin vesicles, we next investigated 
whether inhibition of caveolin vesicle formation either by treatment with Nystatin or by siRNA 
has similar effects on IL-1 induced ERK phosphorylation as the knockout or inhibition of 
sdc4. Indeed, when we treated wild type FLS with Nystatin, FLS lost their ability to respond 
to IL-1 with a phosphorylation of ERK (Fig. 2f). As Caveolin-1 (Cav-1) is a key component of 
caveolin vesicles (16), and phosphorylation of Cav-1 constitutes a key step in caveolin 
vesicle translocation (17), we also knocked down Cav-1 with specific siRNA and found that 
Cav-1 deficient FLS, in a similar way as Nystatin treated cells, lost their ability to 
phosphorylate ERK in response to IL-1 (Fig. 2g). In line with these observations, treatment of 
wt FLS with Nystatin, significantly reduced the presentation of the IL1R1 on the cell surface 
(wt: 6.15 ± 0.40, wt nystatin: 3.31 ± 0.11, p=0.009), but had only minor additional effects on 
sdc4 deficient cells (Sdc4: 3.90 ± 0.27, Sdc4 nystatin: 2.58 ± 0.19) (Fig. 2h). At the mRNA 
level, we found no differences in Cav-1 expression between wt and sdc4-/- FLS (wt: 0.99 ± 
0.17, sdc4: 0.99 ± 0.18, p= 0.995) (Fig. 2i). However, when studying the presence of 
phosphorylated Cav-1 by sucrose gradient centrifugation, we found that sdc4-/- FLS contain 
far less phospho-Cav-1 than wt cells after stimulation with IL-1 beta (Fig. 2j).  
 
Sdc4 blocking antibody reduces IL1R1 surface presentation leading to reduced RA 
symptoms in the hTNFtg RA mouse model  
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As these data indicated that sdc4 is an important regulator of IL-1 signaling, we tested 
whether the application of specific antibodies (Ab) raised against the extracellular 
dimerization motif of sdc4 [6, 12] would result in a reduction of ERK phosphorylation as a 
marker for IL-1 signalling activation. Incubation of FLS with the blocking Ab clearly inhibited 
the IL-1 induced ERK-1/2 phosphorylation to a comparable extent as the loss of Sdc4 (Fig. 
3a). Moreover FACS analyses of FLS treated with the blocking Sdc4 Ab or IgG revealed that 
anti-sdc4-Ab treated cells exhibited less IL1R1 on their surface than did IgG treated FLS (wt: 
7.30 ± 0.29, sdc4: 4.29 ± 0.21, p=0.001) (Fig. 3b). 
Additionally, we observed a reduction in Sdc4 dimers as early as 5 minutes after IL-1 
stimulation (untreated: 1.27 ± 0.30, IL-1: 0.36 ± 0.13, p= 0.0091) (Fig. 3c). These data 
indicate that the dimerization of sdc4 is involved in IL1R1 trafficking after IL-1 stimulation. 
Incubation of FLS with the blocking scd4 Ab or the combination of IL-1 and the blocking scd4 
Ab exhibited no additional effect (Fig. 3c).  
These data raised the question of whether the timely application of our blocking anti-sdc4 
antibodies downregulates IL-1R1 and prevents cartilage destruction in human TNFα 
transgenic (hTNFtg) mice to a similar extent as we found in Scd4-/- mice previously [7] and 
as also observed in mice that lack IL-1R1. Indeed, injection of the antibodies into eight week 
old hTNFtg mice three times per week for four weeks protected the treated joints nearly 
completely from cartilage damage (Fig. 3d) with decreased pannus area (IgG:21.92 ± 3.63, 
α-Sdc4-Ab:6.795 ± 2.56, p= 0.0144, n=4), cartilage erosion (IgG: 36.19 ± 4.96, α-Sdc4-
Ab:10.19 ± 3.99, p= 0.0065, n=4), decreased proteoglycan loss (IgG: 68.82 ± 4.17, α-Sdc4-
Ab: 18.14 ± 4.47, p= 0.0002, n=4) and decreased expression of MMP-3 (IgG: 4.43 ± 0.62, α-
Sdc4-Ab: 0.68 ± 0.48, p= 0.0007, n=4) (Fig. 3d). The extent to which the antibody inhibited 
cartilage damage was comparable to that in hTNFtg mice that lacked Sdc4 (10) or IL-1R1 
(Fig. 3d). This was also seen in histomorphometric analyses, where the inhibition of sdc4 and 
the loss of the IL-1R1 gave very similar results those from the hTNFtg background (Fig. 3d). 
 
Discussion 
In this work, we have investigated how sdc4 modulates the response of fibroblasts to the 
inflammatory cytokine IL-1 and asked the question if specific, antibody-mediated targeting of 
sdc4 may alter the response of fibroblasts to IL-1, particularly during chronic destructive 
arthritis. Since various proteins have been found to bind to the GAG chains of sdc4 [13], and 
IL-1ß binding to GAG chains of both the heparan sulfate type and the chondroitin sulfate type 
have been described before [14], the demonstration that IL-1 can bind to the side chains of 
Sdc4 was no surprise. However, we could show that binding of IL-1 to the sdc4 GAG chains 
also results in the dimerization of sdc4 which has been suggested to constitute a prerequisite 
for sdc4- mediated intracellular signaling [15, 16]. This is of importance because a clear 
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function of the extracellular domain in dimerization had not previously been shown, while in 
our studies Abs against the dimerization domain of sdc4 not only inhibited dimer formation 
but also reduced IL-1 induced ERK phosphorylation in a similar way as did the loss of sdc4, 
suggesting that sdc4 dimer formation by itself facilitates the IL-1 response of fibroblasts. It 
may be hypothesised that IL-1 induced dimerization of sdc4 results from the interaction of IL-
1 with its cognate receptor rather than from the direct binding of IL-1 to sdc4. This was not 
seen when whole cell lysates were used, most likely reflecting the dynamics of sdc4 
internalisation in response to IL-1. However, dimerization of sdc4 in response to IL-1 was 
also seen in IL-1R deficient cells, suggesting that the IL-1R is not required for IL-1 to induce 
scd4 dimerization and, thus, signaling through this pathway. Recent data suggest that 
trafficking of the IL-1R1 involves the formation of caveolin vesicles [8]. In line with these data, 
we found that the inhibition of caveolin vesicle formation either by treatment with Nystatin 
[17] or through RNAi has similar effects on IL-1 induced ERK phosphorylation as had the 
knockout of sdc4 or the Ab- mediated inhibition of sdc4 dimerization. An interaction of Sdc4 
with caveolin vesicles has been previously proposed [18], and it has been shown that sdc4 is 
involved prominently in caveolin-mediated integrin recycling. In line with these findings, we 
detected a reduced presence of IL1R1 on the cell surface in sdc4 deficient fibroblasts, which 
was dependent on caveolin vesicle formation. The time course of IL1R1 surface presentation 
in combination with Sdc4 dimer detection indicate that the presence of Sdc4 critically 
regulates the surface presentation of IL1R1. Thus it may be hypothesised that upon induction 
of IL1 signaling, the IL1R1 is reduced from the cell surface at the same time as Sdc4 
dimerization is reduced. To show the in vivo relevance of the described mechanism, we 
applied the blocking anti-sdc4 antibody to hTNFtg mice that are a model for human RA 
disease. Importantly, treatment with the blocking antibody resulted in a similar phenotype as 
found in the IL1R1 knockout, as well as the Sdc4-/- hTNFtg mouse [7]. However, the effect of 
the blocking sdc4-antibody was not as strong, as the effect of the complete knockout, which 
might be explained by residual sdc4 on the cell surface that was not blocked by the sdc4 
antibody, as we did not titrate for the maximum effect of the blocking antibody. 
Collectively, our data demonstrate that dimerization of sdc4 is critically involved in IL1 signal 
transduction and IL1R1 surface presentation via caveolin-dependent mechanisms and those 
antibodies that specifically inhibit sdc4 dimerization may support anti-IL-1 strategies in 
diseases such as inflammatory arthritis. 
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Materials and Methods 
Blocking sdc4 antibodies 
The blocking sdc4 antibodies were generated against the peptide 
NAQPGIRVPSEPKELEENEVIPKRAPSDV of the extracellular part of sdc-4. Rabbits were 
immunized with the synthetic peptide and the antibodies were purified by Pineda (Berlin, 
Germany). The polyclonal antibodies of two different immunized rabbits were tested for sdc4 
specificity using western blot (suppl. Fig 1 and c). The specificity of the antibody used for the 
treatment of hTNFtg mice was also tested in immunohistological stainings of wt and sdc4 ko 
fibroblasts (suppl. fig 1 b). To test the reproducibility of generating blocking sdc4 antibodies 
when using the extracellular part of sdc4 for immunization, we tested the polyclonal 
antibodies of another immunized rabbit for the capability to inhibit IL-1 induced ERK1/2 
phosphorylation (representative western blot, suppl. fig 1d). 
Animals and treatment 
hTNFtg mice (strain Tg197) have been described previously [19] and were maintained on the 
C57BL/6 genetic background. We generated all data from sex and age-matched littermates. 
The hind paws of eight week old hTNFtg mice were either treated with our blocking sdc4 
antibodies or an IgG control (Chrome Pure Rabbit IgG, Dianova) by p.a. injections of 50 µl 
into the hind paw, three times weekly for four weeks. Afterwards, mice were euthanised and 
the hind paws were prepared for histological analysis. All animal experiments were 
authorised by the Animal Use Committee in Muenster under the file reference 84-
02.04.2014.A465. 
Arthritis assessment  
Histological analysis was conducted on 4% phosphate-buffered paraformaldehyde-fixed, 
decalcified paraffin sections of hind paw joints. Paraffin sections were stained with toluidine 
blue. Quantification of pannus area, destained cartilage and cartilage erosion were 
performed using a Zeiss Observer Z1 microscope (Carl Zeiss) and the Zeiss AxioVision 4.7.1 
software. 
Immunohistochemistry 
MMP-3 staining was performed using anti-MMP-3 antibody (Abcam) and subsequent 
detection using the alkaline phosphatase reagent from the Vector Red SK-5100 substrate 
(Vector Laboratories). For IL-1R staining, the anti-IL-1R antibody (Bioss) was used. The 
staining was visualized using the DAB reagent from the DAB Peroxidase (HRP) kit SK-4100 
(Vector Laboratories). Quantification was performed using Image-Pro Plus. IL-1R positive 
cells (%) were measured by dividing the number of positive stained cells by the total cell 
number. To calculate the MMP-3 positive joint area (%) a rectangle of fixed size was laid 
over each joint and the positive stained area was divided by the total area of the rectangle.  
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Histology 
All studies were approved by the ethics committees of the University Hospital Muenster. 
Samples of synovial tissues from patients with RA or OA were obtained from joint 
replacement surgery (Ethics committee Muenster, approval number 2009-049-f-s). Tissue 
samples from RA and OA patients were fixed in 4% paraformaldehyde overnight, embedded 
into paraffin and sectioned into 5 µm slices. Tissue sections were pre-treated with 1x 
Trypsin/EDTA (PAA Laboratories, Pasching, Austria) for 20min at 37°C, blocked with 10% 
horse serum and stained with a monoclonal scd4 antibody (Santa Cruz, clone 5G9) for 
human tissue sections over night at 4°C. Immunohistochemistry was performed with an 
alkaline phosphatase technique using Vectastain ABC-A, Vector Red Substance and 
secondary biotinylated antibodies (Vector Laboratories, Burlingame, CA). Nuclei were 
counterstained with methyl green (Vector Laboratories, Burlingame, CA).  
Immunocytochemistry 
RASF and OASF were seeded on glass cover slips, fixed with 4% paraformaldehyde 
including 0.1% Tween 20, blocked with 1% BSA and stained with the monoclonal scd4 
antibody 5G9 and an Alexa488 goat anti-mouse antibody (Molecular Probes) for detection of 
scd4 expression. Propidium iodide (Sigma) was used to stain the nuclei.   
Murine synovial fibroblasts 
Murine synovial fibroblasts were isolated from hind paws. Joints were dissociated and 
digested with Collagenase IV (Worthington) and cultured in DMEM (Sigma) supplemented 
with 10 % FCS (PAA). The murine fibroblast cell line NIH/3T3 was used for transfection 
experiments. All cells were cultured in DMEM with 10% FCS at 37°C and 5% CO2 until 
passages 4-6. Cells were stimulated for the indicated time period with 10 ng/ml murine IL-1 
beta (R&D systems) or 10 ng/ml human TNF alpha (R&D systems). 
Immunoprecipitation 
Immunoprecipitation was performed using Anti-FLAG M2 Magnetic Beads (Sigma) according 
to the manufacturer’s protocol. Therefore, we transfected HEK cells either with FLAG tagged 
full length sdc4 (flag-sdc4wt) or with a FLAG-tagged mutant of sdc4 in which all GAG binding 
serine residues were replaced by alanine (flag-sdc4S3A) and that therefore has no GAG side 
chains. 
The next day, cells were incubated with 100 ng IL-1beta or TNF alpha (both R&D) for 1 h at 
37 °C in DMEM medium without FCS. IL-1 was detected using an IL-1beta Antibody 
(#12242, Cell signaling) and TNF using a TNF alpha antibody (#3707, Cell signaling). True 
Blot secondary antibodies (Rockland) were used to ensure, that IgG fragments from the 
antibodies attached to the beads were not detected. 
Isolation of caveolae 
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Isolation of caveolae was done according to the protocol of Ostrom and Insel [20] by sucrose 
gradient centrifugation. All the buffers used were identical to the protocol and proteinase 
inhibitors as well as phosphatase inhibitor were present in the lysis buffer, sucrose/MBS and 
Triton-X 100 buffer. After cell homogenization of a complete, confluent cell culture flask, the 
lysate was loaded on the described sucrose gradient and centrifugation was performed at 
260,000 g for 18 h at 4 °C. Then, the gradient was separated into 250 µl fractions and 
ethanol precipitation was performed.  
As lipid rafts and caveolae were more buoyant than other cellular parts, fraction 2 between 
the 35 % to 5% sucrose borderline was analysed using western blot analysis. 
Western blotting 
Total cell extracts were obtained using NP-40 buffer (150 mM sodium chloride, 1 % NP-40, 
50 mM Tris HCl pH 8) containing protease inhibitor cocktail (Roche) and phosphatase 
inhibitor (Roche). The extracts were resolved by SDS-PAGE and transferred to a 
polyvinylidene difluoride membrane (GE Healthcare). The proteins were detected with 
appropriate antibodies using the ECL detection system (GE Healthcare) or Super Signal 
West Femto (Life Technologies). Antibodies against the following proteins were used: Scd4 
(Pineda), Caveolin-1 (Abcam), p-Caveolin-1 (Tyr14), Erk1/2, p-Erk1/2, il-1beta, and 
TNFalpha (all from Cell signaling). 
FACS Analysis 
Confluent FLS cells were washed once with PBS and harvested by incubating the monolayer 
in 10 ml PBS containing 0.02% EDTA and detaching cells by firmly rocking. Unspecific 
staining was reduced by incubating the re-suspended cells in HBSS containing 1% BSA, 2% 
bovine FCS and 0.1% NaN3 in the presence of 0.2 µl/well Fc blocking antibody (BD 
Biosciences) for 10 min on ice. For TNFR1 staining, 40 µl cell suspension in HBSS plus 
supplements were incubated with anti-TNFRI antibody (Abcam) or the equal concentration of 
isotype control rabbit IgG (R&D systems.) A secondary anti-rabbit A488 antibody (Life 
Technologies) was used. For IL1R1 staining the anti-IL1R1 PE antibody (BD Biosciences) or 
the respective isotype control (BD Biosciences) was used. For both stainings, dead cells 
were excluded by incubating with DAPI (Life Technologies) before recording on a FACS 
Canto II cytometer. 
ELISA 
Wt and Sdc4-/- synovial fibroblasts were cultured in DMEM (Sigma) supplemented with 10 % 
FCS (PAA). Confluent cells were stimulated with 10 ng murine IL-1 beta or 100 ng murine 
TNF alpha (R&D systems) for 8 h. Cell culture supernatants were assessed for total MMP-3 
by ELISA (R&D systems) according to the manufacturers protocol. 
siRNAs and transfection 
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Caveolin-1 siRNA was synthesized by Dharmacon (Lafayette, CO, USA) under the reference 
ON-TARGETplus Mouse Cav1 siRNA (J-058415-05-0050). Transfection of siRNAs was 
performed using N-TER nanoparticle siRNA transfection system (Sigma) according to the 
manufacturer’s instructions. Wt synovial fibroblasts were transfected again after 48 h and 
cells were used after 72 h for western blot analysis.  
Inhibition of caveolin vesicle formation via Nystatin 
Formation of caveolin vesicles was inhibited using Nystatin (Sigma). Nystatin powder was 
dissolved in DMSO in a concentration of 10 mg/ml and used in a final concentration of 20 
µg/ml dissolved in FCS-supplemented DMEM. Cells were pre-treated with Nystatin for 45 
minutes prior to stimulation and overnight for flow cytometric analysis. 
Semi-quantitative PCR from human and murine synovial fibroblasts 
Total RNAs from SF was isolated using TRIzol reagent (Life technologies) according to the 
manufacturer’s protocol. cDNAs were synthesized by reverse-transcriptase using the cDNA 
synthesis kit (Life technologies) with oligo dT primers. Primer sequences were as followed: 
Caveolin-1 forward 5’- AAC ATC TAC AAG CCC AAC AAC AAG G-3‘ and reverse 5’- GGT 
TCT GCA ATC ACA TCT TCA AAG TC-3’; GAPDH forward 5’  AGC AAG GAC ACT GAG 
CAA GAG AGG 3’ and reverse 5’  GGG TCT GGG ATG GAA ATT GTG AGG 3’; il-1r forward 
5’  CCC GAG GTC CAG TGG TAT AAG AAC 3’ and reverse 5´  ACT CCG AAG AAG CTC 
ACG TTG TC 3’; tnfrI forward 5’  ACC TGT CAG TGA GGT AGT CCC AAC 3’ and reverse 5’  
ACA GAA TCG CAA GGT CTG CAT TG 3’, human scd4 forward 5´-cgg gca gga atc tga tga 
ctt tga-3´ and reverse: 5´-gct tca cgc gta gaa ctc att ggt-3´;  
 
Proximity ligation assay 
Gene synthesis of the complete murine syndecan-4 cDNA was performed by GeneArt 
(Invitrogen). Full length syndecan-4 cDNA was mutated such that the HA epitope was 
inserted between I32 and D33 of the extracellular domain. The cDNA was then cloned into the 
lentiviral vector pLNT-SFFV-MCS-eGFP and lentivirus produced in HEK293t cells using 
conventional procedures. NIH3T3 fibroblasts (HPA laboratories) were then transfected using 
the supernatant transfer method. NIH3T3 expressing Sdc4-HA-tagged (GFP+) and 
untransfected cells were grown on 8-well chamber slides. Cells were treated for 5 min with 
50 µl serum-free Optimem containing either 1:10 Rabbit anti-Sdc4 Ab (#1283, Lot 1405, 575 
ng/µl), IL-1β (10 ng/ml) or both. Following treatments, medium was taken off, cells washed in 
PBS at RT, fixed in 4% PFA for 15’ at RT. After a 5’ wash in PBS, PFA was quenched by 
incubating cells with 0.1M NH4Cl for 10min at RT. Proximity ligation assay was performed as 
per manufacturer’s instructions (Duolink, Sigma Aldrich) using mouse IgG1 anti-HA Ab 
(Covance) and plus and minus anti-mouse probes. Images were taken using confocal 
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microscopy (Carl Zeiss LSM 700) with 63x oil objective and analysed using ImageJ software 
(NIH). Results were expressed as number of PLA dots per µm2 of GFP+ cells. 
  
Cross linking 
In order to stabilize the formed scd4 multimers, crosslinking was applied to cell surface 
proteins subsequent to multimerization experiments. Therefore, cells were washed four times 
with ice-cold PBS directly after IL-1 stimulation and then incubated with 1 - 5 mM of the 
crosslinking reagent BS3 (Thermo Fischer, Dreieich, Germany) at room temperature for 30 
min. Finally, 15 mM Tris-HCl (pH 7.5) was added for 15 min to quench the reaction and after 
washing with PBS, the cells were directly lysed or frozen at -80 C. 
Statistical analysis 
All data are means ± SEM. Biological replicates are stated as n. Mean values of technical 
replicates are stated as n= 1. Statistical analysis was performed using GraphPad Prism 
Software, 6 (Graph Pad Software Inc., San Diego, CA, USA). Differences between groups 
were examined for statistical significance using an ANOVA with post-hoc t-test and 
Bonferroni correction for multiple testing, or Welch’s t-test; *p<0.05. 
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Figure legends. 
 
Figure 1: Scd4 reduces IL-1ß signalling by direct binding to the HS side chains and induction 
of sdc4 dimerization. a, Representative images of enhanced syndecan-4 staining in tissue 
sections from rheumatoid patients (RA) compared to osteoarthritic patients (OA) (red, 200x 
magnification) (n= 10). Quantitative real-time PCR of syndecan-4 mRNA levels in RASF and 
OASF revealed upregulation of syndecan-4 in RA patients (n=10, p<0.05). b, Representative 
immunohistochemical staining of synovial tissue sections of hTNFtg and wild type mice with 
monoclonal syndecan-4 antibody showed a high syndecan-4 expression in the pannus tissue 
(red, 200x magnification) (n= 8). Quantitative real-time PCR showed a 21.6-fold upregulation 
in synovial fibroblasts of hTNFtg mice as compared to synovial fibroblasts of wild type mice 
normalized to HPRT (n= 4). c, TNFalpha stimulation of wt and sdc4-/- synovial fibroblasts 
revealed no difference in Erk1/2 activation (n≥ 3). d, Sdc4-/- synovial fibroblasts showed a 
reduced Erk1/2 activation in response to IL-1 stimulation compared to wt (n≥ 3). e, Wt and 
Sdc4-/- synovial fibroblasts were stimulated with TNFalpha (n≥ 3), (f) or IL-1β and 
supernatants were used for MMP-3 ELISA (n≥3 , *p<0.05). g, Representative western blot of 
HEK cells were transfected with FLAG tagged full length sdc4 (flag-sdc4wt) or with a FLAG-
tagged mutant of sdc4 holding no GAG side chains (flag-sdc4S3A). IL-1, however, could be 
detected in the eluate of the GAG side chain-holding construct (flag-sdc4wt), but not from the 
side chain-lacking construct (flag-sdc4S3A). h, Representative western blot of IL-1-induced 
sdc4 dimerization is independent of IL1R1. i, Representative western blot of Sdc4 
dimerization induced by IL-1β. Figure a and b were analysed for statistical significance using 
a Welch’s t-test. Figure c, d, e and f were analysed using an ANOVA with post-hoc t-test. 
 
Figure 2: Sdc4 regulates IL1R1 trafficking upon IL-1 stimulation. a, FACS analysis revealed 
that IL-1R1 surface presentation was significantly reduced in Sdc4 deficient synovial 
fibroblasts (n=3, *p<0.05). b, Quantitative real-time PCR showed no difference in IL-1R1 
mRNA expression levels comparing wt and Sdc4-/- synovial fibroblasts normalized to 
GAPDH (n≥5, *p<0.05). c, TNFR1 surface presentation was comparable between wt and 
Sdc4-/- synovial fibroblasts as shown by FACS analysis (n=3 , *p<0.05). d, TNFR1 mRNA 
expression was equal comparing wt, Sdc4-/- and IL1R1-/- synovial fibroblasts by quantitative 
real-time PCR (n≥5, *p<0.05). e, FACS analysis of IL-1R1 surface presentation was 
significantly reduced in wt synovial fibroblasts after 10 minutes of IL-1 stimulation, whereas 
no change was observed in Sdc4 deficient fibroblasts (n=4, *p< 0.05). f, The caveolin 
inhibitor Nystatin reduced activation of Erk1/2 in wt synovial fibroblasts in response to IL-1 
stimulation. g, Knockdown of caveolin-1 using RNAi abolished activation of Erk1/2 in wt 
synovial fibroblasts. h, Pre-incubation with Nystatin reduced IL1R1 surface presentation in wt 
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synovial fibroblasts to the levels on Sdc4-/- cells (n=3). i, Quantitative real-time PCR showed 
no difference in caveolin-1 mRNA levels comparing wt and Sdc4-/- FLS (n≥5, *p<0.05). j, 
Sucrose gradient centrifugation was used to isolate caveolin vesicles after stimulation with 
IL-1. The representative western blot analysis showed a reduced caveolin phosphorylation in 
wt compared to Sdc4-/- synovial fibroblasts (n= 2). Data were analysed for statistical 
significance using an ANOVA with post-hoc t-test.  
 
Figure 3: Sdc4 blocking antibody reduces IL1R1 surface presentation leading to reduced RA 
symptoms in the hTNFtg RA mouse model. a, Inhibition of sdc4 function by a polyclonal 
antibody directed against the membrane proximal part of the extracellular domain of sdc4 
(anti-Sdc4-Ab) resulted in a diminished Erk1/2 activation in wt synovial fibroblasts. b, FACS 
staining revealed that a pre-incubation of wt synovial fibroblasts with anti-Sdc4-Ab led to a 
significant reduction of IL1R presentation compared to IgG treated cells (n=3, *p<0.05). c, 
Syndecan-4 dimerization is inhibited by IL1β stimulation and the blocking α-syndecan-4 
antibody. Proximity ligation assays in NIH/3T3 cells transfected with HA tagged syndecan-4 
reveal fewer dots per area (red) in the presence of both IL1β and syndecan-4 antibody (n=4, 
*p<0.05). d, hTNFtg mice were treated with our blocking anti-Sdc4- Antibodies (anti-Sdc4-
Ab) or non-specific IgG (IgG control) from week 8 to week 12 of age, while hTNFtg x IL1R1-/- 
mice served as control. Representative Toluidine blue and MMP-3 stainings of hind paw 
sections of 12 weeks old hTNFtg mice are shown. Anti-Sdc4-Ab treatment of hTNFtg mice 
caused a strong decrease in MMP-3 levels (red) and inflammation as well as cartilage 
damage Mean areas of synovial pannus tissue, destaining of the cartilage (in percent of total 
cartilage), cartilage erosion (in percent of cartilage) and MMP-3 positive joint area in the 
tarsal joints was measured. Treatment of hTNFtg mice with anti-Sdc4-Ab showed decreased 
pannus formation and reduced MMP-3 levels (red) resulting in the preservation of cartilage in 
comparison to IgG treated hTNFtg mice (n≥4, *p<0.05 at week 12). Figure b, c, and d were 
analysed for statistical significance using an ANOVA with post-hoc t-test.  
 
Suppl. Figure 1: Specificity of blocking sdc-4 antibodies. a.) Western blot with sdc4-/- and 
wildtype (wt) fibroblasts using the sdc-4 blocking antibody 1 to detect sdc4. No signal was 
observed in the sdc4-/- fibroblasts. b.) Immunocytochemistry of wt and sdc4-/- fibroblasts 
using the sdc-4blocking antibody 1. Again, no staining was observed in the sdc4-/- 
fibroblasts. c.) Western blot with sdc4-/- and wildtype (wt) fibroblasts using the sdc-4 blocking 
antibody 2 to detect sdc4. No signal was observed in the sdc4-/- fibroblasts. d.) Inhibition of 
sdc4 function by the sdc4 blocking antibody 2 resulted in a diminished IL-1 induced Erk1/2 
activation in wt synovial fibroblasts. 
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